Quince Therapeutics (NASDAQ:QNCX) Upgraded at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I upgraded shares of Quince Therapeutics (NASDAQ:QNCX) to a strong-buy rating in a report released on Tuesday, Zacks.com reports.

Quince Therapeutics Stock Performance

NASDAQ QNCX opened at $1.19 on Tuesday. The firm’s fifty day moving average price is $0.74 and its two-hundred day moving average price is $0.80. Quince Therapeutics has a 1 year low of $0.51 and a 1 year high of $1.43. The firm has a market capitalization of $51.43 million, a P/E ratio of -1.57 and a beta of 0.86. The company has a current ratio of 6.15, a quick ratio of 6.15 and a debt-to-equity ratio of 0.29.

Quince Therapeutics (NASDAQ:QNCX) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.18) EPS for the quarter.

Insider Activity

In related news, CEO Dirk Thye purchased 77,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The shares were acquired at an average price of $0.69 per share, for a total transaction of $53,475.00. Following the purchase, the chief executive officer now owns 766,941 shares in the company, valued at approximately $529,189.29. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Quince Therapeutics news, President Charles S. Ryan acquired 48,387 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was acquired at an average price of $0.65 per share, for a total transaction of $31,451.55. Following the purchase, the president now directly owns 122,461 shares of the company’s stock, valued at $79,599.65. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Dirk Thye bought 77,500 shares of the stock in a transaction dated Thursday, August 29th. The shares were acquired at an average cost of $0.69 per share, for a total transaction of $53,475.00. Following the completion of the acquisition, the chief executive officer now directly owns 766,941 shares of the company’s stock, valued at approximately $529,189.29. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 158,887 shares of company stock valued at $105,609 over the last ninety days. 16.80% of the stock is currently owned by company insiders.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.